GSK’s Blenrep Shows Promising Myeloma Treatment Results

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline’s recent DREAMM-8 phase III clinical trial reports a nearly 50% reduction in disease progression or death when using their Blenrep combination treatment for relapsed or refractory multiple myeloma, compared to the standard of care. The Blenrep treatment, consisting of belantamab mafodotin combined with pomalidomide and dexamethasone, has not reached median progression-free survival at 21.8 months follow-up, showing a promising improvement over the 12.7 months with the standard bortezomib combination. These findings could represent a significant advancement in the treatment of multiple myeloma, meeting a high unmet need for effective therapies post initial treatment relapse.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.